Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
US12428473B2 · kind B2 · utility
0Cited by
59References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 15, 2021 |
| Grant date | Sep 30, 2025 |
| Priority date | — |
| Expiry date | Jul 10, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.